Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases through the manipulation of gene regulation
The company leverages its proprietary technology platform to identify and develop small molecules that target specific genes and cellular pathways, aiming to disrupt the disease process at the molecular level. Syros is dedicated to advancing its pipeline of product candidates, which are designed to selectively modulate gene expression and provide new treatment options for patients with unmet medical needs. Through its research and development efforts, Syros aims to improve patient outcomes and ultimately transform the landscape of disease management.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Syros Pharmaceuticals, Inc. (NASDAQSYRS) (the “Company”) today announced that its Board of Directors (the “Board”) has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market (“Nasdaq”) and the deregistration of its common stock in order to terminate and suspend the Company’s reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act").
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans.
Syros Pharmaceuticals (NASDAQSYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syros’ proprietary oral, selective, retinoic acid receptor alpha (RARα) agonist.
Syros Pharmaceuticals (NASDAQSYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update.
Syros Pharmaceuticals (NASDAQSYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. (“Syros” or “the Company”) (NASDAQSYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SYRS.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. (“Syros” or “the Company”) (NASDAQSYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SYRS.
Syros Pharmaceuticals (NASDAQSYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial at the Society of Hematologic Oncology (SOHO) Annual Meeting taking place September 4-7, in Houston, Texas. Additionally, Syros announced that company management will participate in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11 in New York City.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. (“Syros” or “the Company”) (NASDAQSYRS) for violations of the securities laws.
